Skip to content
Search

Latest Stories

Mixed views on benefits of cannabis oil products

By Nadeem Badshah

TOP pharmacists are divided on the benefits of cannabis oil products being sold to treat pain.


Around 1.3 million UK consumers spend £300 million a year on CBD goods, research has shown, with a number of specialist stores opening in high streets across the country.

Cannabidiol, or CBD, is a chemical found in the cannabis plant. The products are legal if sold as a food supplement but require medical permission if offered as a medicine.

It has led to a string of CBD medical marijuana card online doctor infused products including oils, muscle balms, anti-ageing creams and sex lubricants. A Hemp and CBD Expo is taking place at the NEC in Birmingham on February 29-March 1.

Pharmacist Nader Siabi has urged people to buy them from chemists to get advice on whether it is dangerous to take with other medicine and to do research on the CBD content of products.

Siabi, from the North East London Pharmaceutical Committee, told Eastern Eye: "Some companies made claims they were not able to substantiate but one produced the lab data and batch numbers.

"There is no scientific claims for the benefits but people who use them say it is working. We put CBD in the pharmacy and from the first week people are buying them.

"We are selling drugs, sprays and balm for joint pains for example. We see people coming for repeat purchases, they have found some benefit.

"Whether it is a placebo effect or it is helping them, I believe in it 100 per cent now due to patient feedback.

"You have to do your due diligence and ensure patients have the necessary information about drug interactions [mixing with other medicine]."

CBD products contain a non-psychoactive chemical found in the hemp plant. It has become trendy among people in the past year over claims it helps with pain and insomnia.

Between 2002 and 2012 there were nine published studies on the use of CBD for the treatment of pain.

By 2017, there had been 30 with most showing potential benefits for pain relief but the studies involved small participant numbers and mostly rats.

Vikesh Patel, who owns four pharmacists in south east England, said he is sceptical about CBD.

He told Eastern Eye: "There is no evidence of the product claims on anxiety, constipation.

"If it's that great why haven't they done a clinical trial?

"If the user is not intellectual and learned enough, they can be fobbed off.

"We are selling CBD oral drops, skin creams and sprays out of business need and we go with companies that have some data and do not sell to under 18s.

"Before it was homeopathic medicines, there was no evidence for it, and they clamped down on it being sold in pharmacies."

Since last October, cannabis-based products can be prescribed by specialist hospital doctors in cases of children with rare, severe forms of epilepsy and adults with vomiting or nausea caused by chemotherapy or muscle stiffness from multiple sclerosis.

A spokesman for the National Pharmacy Association said it would welcome more research and guidance that makes it easier for manufacturers, health care professionals, retailers and consumers to make informed choices.

“Our advice to pharmacists considering whether to stock non-medicinal CBD products is to ensure they are acting legally and putting the needs of patients first – which is the same advice we’d give about all other products sold or supplied in pharmacies.

"In the case of non-medicinal CBD products, pharmacists should take account of current Home Office guidance.

“Currently the evidence about the long term effects of these products is limited and the regulations are complex."

Kings College London (KCL) secured funding to carry out a large-scale trial to test whether CBD could be useful in treating young people at high risk of developing psychosis.

Dr Sagnik Bhattacharyya, from KCL's psychiatry, psychology and neuroscience unit said few of the claims for CBD's effects have been tested but scientists are looking whether large doses could help treat severe mental health problems.

He added: "We have carried out a couple of studies where we show that a single 600mg dose of cannabidiol can normalise brain function in key regions we know are abnormal in people with psychosis."

More For You

UK economy contracts unexpectedly in January

Chancellor Rachel Reeves speaks while holding roundtable discussion during a visit to RAF Waddington in eastern England. (Photo by YUI MOK/POOL/AFP via Getty Images)

UK economy contracts unexpectedly in January

BRITAIN's economy unexpectedly shrank in January, official data showed on Friday (14), piling more pressure on the Labour government ahead of its Spring Statement on the economy.

Gross domestic product contracted 0.1 per cent in the month after GDP rose 0.4 per cent in December, the Office for National Statistics (ONS) said in a statement.

Keep ReadingShow less
Pakistan seeks £3.4bn bank loan to tackle mounting energy sector debt

Pakistan’s government is the largest shareholder or owner of most power companies

Pakistan seeks £3.4bn bank loan to tackle mounting energy sector debt

Eastern Eye

PAKISTAN government is negotiating a 1.25 trillion Pakistani rupee (£3.4 billion) loan with commercial banks to reduce its bulging energy sector debt, the power minister and banking association said.

Plugging unresolved debt across the sector is a top priority under an ongoing $7bn (£5.4bn) International Monetary Fund (IMF) bailout, which has helped Pakistan dig its way out of an economic crisis.

Keep ReadingShow less
Deliveroo posts first annual profit after 12 years

A Deliveroo rider near Victoria station in London, England. (Photo by Dan Kitwood/Getty Images)

Deliveroo posts first annual profit after 12 years

FOOD DELIVERY app Deliveroo announced on Thursday (13) its first annual profit as orders and revenue rose, while the 12-year old company sees further growth despite exiting Hong Kong.

The milestone follows sizeable full-year losses owing to high investment costs since American Will Shu founded the company in 2013 and made Deliveroo's first delivery in London.

Keep ReadingShow less
Government to abolish payments regulator to boost growth

Keir Starmer (R) and Rachel Reeves host an investment roundtable discussion with members of the BlackRock executive board at 10 Downing Street on November 21, 2024 in London, England. (Photo by Frank Augstein - WPA Pool/Getty Images)

Government to abolish payments regulator to boost growth

PAYMENTS REGULATOR will be abolished and its remit absorbed by another financial regulator, the government said on Tuesday (11), as it aims to cut red tape in favour of growth.

The Payment Systems Regulator (PSR), which oversees systems including MasterCard and bank transfers, tackles problems such as fraud, excessive fees and lack of competition among banks and payment providers.

Keep ReadingShow less